Loading... Please wait... Loading... Please wait...
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its propriet...
North Bay Resources Inc. (OTC:NBRI) has entered into a 50-50 joint venture earn-in agreement with MGX Minerals for the Fran gold project located in British Columbia. North Bay can earn up to an initia...
Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024;...
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023....
Enhances strategic flexibility and control of key gene editing technologies and programs Enhances strategic flexibility and control of key gene editing technologies and programs...
- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 20...
Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024...
EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeut...
Metagenomi just raised $94 million in its initial public offering. It now has enough money to last it for a few years....
